已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib

奥西默替尼 T790米 医学 外显子 阿法替尼 突变 基因复制 肿瘤科 癌症研究 内科学 基因 遗传学 表皮生长因子受体 癌症 埃罗替尼 吉非替尼 生物
作者
Jiasheng Xu,Qidi Jiang,Hua Xu,An-Wen Liu,Long Huang
出处
期刊:Journal of Thoracic Oncology [Elsevier]
卷期号:15 (4): e49-e51 被引量:4
标识
DOI:10.1016/j.jtho.2019.11.026
摘要

Previously, scientists have reported patients with NSCLC with insertion or deletion mutation in exon 19 of EGFR gene.1Peiyi X. Enjie L. Pan L. Wencai L. Guozhong J. A case of primary resistance to gefitinib due to novel deletion-insertion mutation of EGFR exon 19 in NSCLC.J Thorac Oncol. 2019; 14: e117-e119Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar, 2Silvia L.M. Roberta M. Daniele C. et al.Acquired BRAF G469A mutation as a resistance mechanism to first-line osimertinib treatment in NSCLC cell lines harboring an EGFR exon 19 deletion.Target Oncol. 2019; 14: 619-626Crossref PubMed Scopus (26) Google Scholar, 3van Kempen L.C. Wang H. Aguirre M.L. et al.Afatinib in osimertinib-resistant EGFR ex19del/T790M/P794L mutated NSCLC.J Thorac Oncol. 2018; 13: e161-e163Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar, 4Ancevski H.K. Friedland D.M. Villaruz L.C. Burns T.F. First-line osimertinib in patients with treatment-naive somatic or germline EGFR T790M-mutant metastatic NSCLC.J Thorac Oncol. 2018; 13: e3-e5Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar Here, we report two patients with NSCLC with a novel duplication mutation in their EGFR gene who responded well to osimertinib. A 67-year-old woman who never smoked presented with convulsion and numbness to our hospital. The plain magnetic resonance imaging (MRI) scan of the brain revealed some nodules over her right parietal lobe, and these nodules were suspected to be a metastatic tumor. The patient then had a thoracic computed tomography (CT) scan, which revealed a tumor with peripheral obstructive inflammation in the inferior lobe of the left lung and multiple swollen lymph nodes in the mediastinum. Lung biopsy and immunohistochemistry staining were performed, which indicated NSCLC. Taking all the results together, this patient was diagnosed with NSCLC (cT1cN2M1b stage IVA) with brain metastasis. Next-generation sequencing indicated a rare duplication mutation in EGFR gene exon 19 (p.I740_K745dupIPVAIK) (Figs. 1A). The patient did not have an operation, but instead was started on osimertinib treatment. After 8 weeks, brain MRI showed disappearance of nodules, and thoracic CT scan showed diminished tumor and shrunken lymph nodes in the left lung (Fig. 1B). Another 59-year-old female patient visited our orthopedics department for paroxysmal dull pain in the lumbosacral region. The MRI indicated multiple focuses of bone destruction and multiple enhanced focuses in cerebral hemisphere surface and subcortical areas, which were suspected to be metastatic tumors. The thoracic CT showed a tumor in the dorsal inferior region of the right lung, and the tumor cells had metastasized to the right pleura and several lymph nodes of the mediastinum. Similarly, the percutaneous biopsy and immunohistochemistry staining indicated NSCLC, and next-generation sequencing revealed a duplication in EGFR gene exon 19 (p.I740_K745dupIPVAIK) and a splicing mutation in TP53 gene exon 3 (Figs. 2A). This patient was ultimately diagnosed with NSCLC stage IV and 1 week later received palliative radiotherapy to the bone for 15 days. On the fifth day of radiotherapy, the patient started osimertinib treatment together with bevacizumab. Four weeks after treatment, the tumor in the inferior dorsal aspect of the lung and lymph nodes in the mediastinum shrank, and the brain metastases disappeared (Fig. 2B). To the best of our knowledge, the two cases reported in this article were the first with duplication mutation (p.I740_K745dupIPVAIK) in the EGFR exon 19 region. Our report provides a feasible therapy for some patients who harbor a rare EGFR mutation such as duplication in exon 19. However, the effect of osimertinib to EGFR 19 duplication, especially its side effect, should be further investigated in subsequent studies. This work was supported by the National Natural Science Foundation of China [grant number 81960571] and the Project of Department of Jiangxi Province Science and Technology Plan [grant number 20192ACB70013]. The authors thank Berry Oncology Corporation for genetic analysis of the patient’s tumor sample.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage应助帆帆采纳,获得10
2秒前
Gaminn完成签到 ,获得积分10
3秒前
9秒前
zpzz完成签到 ,获得积分10
12秒前
正直夜安完成签到 ,获得积分10
13秒前
QYK发布了新的文献求助10
14秒前
研友_Z6Qrbn完成签到,获得积分10
15秒前
Whiaper完成签到,获得积分10
21秒前
22秒前
宣灵薇完成签到,获得积分0
23秒前
端庄大白完成签到 ,获得积分10
25秒前
25秒前
柚子皮蛋瘦肉粥完成签到 ,获得积分10
42秒前
aero完成签到 ,获得积分10
45秒前
人文完成签到 ,获得积分10
56秒前
momo完成签到,获得积分10
1分钟前
暴躁科研菜狗完成签到 ,获得积分10
1分钟前
ldysaber完成签到,获得积分10
1分钟前
Lucas应助Tsingyuan采纳,获得10
1分钟前
1分钟前
Owen应助科研通管家采纳,获得10
1分钟前
1分钟前
寻道图强应助科研通管家采纳,获得30
1分钟前
rocky15应助21采纳,获得10
1分钟前
科研野狗完成签到 ,获得积分10
1分钟前
mov完成签到,获得积分10
1分钟前
科研通AI2S应助归仔采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
李博士发布了新的文献求助10
1分钟前
钮祜禄萱完成签到 ,获得积分10
1分钟前
香妃发布了新的文献求助10
1分钟前
田柾国完成签到,获得积分10
1分钟前
lenon发布了新的文献求助10
1分钟前
111完成签到 ,获得积分10
1分钟前
somebodyzou发布了新的文献求助200
1分钟前
鹤鸣完成签到 ,获得积分10
2分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545217
求助须知:如何正确求助?哪些是违规求助? 2175578
关于积分的说明 5600050
捐赠科研通 1896314
什么是DOI,文献DOI怎么找? 946155
版权声明 565327
科研通“疑难数据库(出版商)”最低求助积分说明 503541